EmeTerm Enters Walmart and Best Buy with New Technology

VANCOUVER, BC, Dec. 16, 2022 /PRNewswire/ — EmeTerm, the anti-nausea wristband developed by WAT Medical Enterprise, Ltd., received its FDA clearance in 2018 as a medical device that manages nausea-induced vomiting. In December 2022, EmeTerm expanded into the retail market by introducing their new product – EmeTerm Explore in Walmart and Best Buy Canada.

With outdoor activities becoming more common than ever since the COVID-19 pandemic, traveling in vehicles is making a return around the world. However, almost one in five people (18%) suffer from car sickness. Over a third of drivers (37%) report that they often take breaks due to a passenger feeling unwell in the car, and many choose to abandon their trips or even avoid them altogether.


EmeTerm Enters Walmart and Best Buy with New Technology

EmeTerm uses neuromodulation, a clinically proven technique to alter the electrical signals within the body. The electric current is sent via the P6 acupuncture point under the wrist. The advantage of neuromodulation in anti-nausea and vomiting is its rapid onset of treatment with zero medically-induced side effects.

EmeTerm Explore comes with natural medical silicon rubber to reduce carbon footprint and prevents allergic reaction. The new design features enhanced device-to-skin electric pulse conduction, making conduction gel unnecessary. This makes the device more affordable and more convenient for day-to-day activities.

Walmart and Best Buy are among the biggest leaders in consumer electronics. This marks the beginning of EmeTerm making its debut and expansion into the global marketplace.

Reference

https://www.emeterm.com/

https://www.walmart.com/

https://www.bestbuy.ca/en-ca 

Subscribe on LinkedIn

Get the free newsletter

Subscribe to MedicaEx for top news, trends & analysis

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.